# Pembrolizumab in Treating Patients With Recurrent Glioblastoma

> **NCT02337686** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Recurrent Glioblastoma
- Recurrent Gliosarcoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Pharmacological Study
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT02337686
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-04-28
- **Primary completion:** 2017-05-24
- **Final completion:** 2026-12-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02337686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02337686, "Pembrolizumab in Treating Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02337686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*